A single dose of the LSD-based therapy DT120 produced rapid antidepressant effects that remained significant through 12 weeks in a pivotal phase 3 trial of major depressive disorder.
Dosages for the Phase IIa programme were selected following the successful completion of the double-blind stage of Beckley Psytech’s Phase I study earlier this year, which showed that BPL-003 was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results